Design, Synthesis, and in vitro antitubercular activity of 1, 2, 3‐triazolyl‐dihydroquinoline derivatives. (18th May 2018)

• Record Type: Journal Article
• Authors: Banu, Saleha; Bollu, Rajitha; Nagarapu, Lingaiah; Nanubolu, Jagadeesh Babu; Yogeswari, Perumal; Sriram, Dharmarajan; Gunda, Shravan Kumar; Vardhan, Divyasphoorthi
• Is Part Of: Chemical biology & drug design. Volume 92:Number 1(2018)
• Page Start: 1315
• Page End: 1323
• Publication Date: 2018-05-18
• Subjects: dihydroquinoline -- molecular docking -- Mycobacterium tuberculosis -- triazole -- X‐ray crystallography; Drugs -- Design -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; 615.19005
• DOI: 10.1111/cbdd.13196
• Languages: English
• ISSNs: 1747-0277

Abstract

Abstract : In the quest for new active molecules against Mycobacterium tuberculosis, a series of dihydroquinoline derivatives possessing triazolo substituents were efficiently synthesized using click chemistry. The structure of6l was evidenced by X‐ray crystallographic study. The newly synthesized compounds were evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv (ATCC27294). The compounds6a, 6g, and6j (MIC: 3.13 μg/ml) showed promising activity when compared to the first‐line drug such as ethambutol. In addition, the structure and antitubercular activity relationship were further supported by in silico molecular docking studies of the active compounds against 3IVX.PDB (crystal structure of pantothenate synthetase in complex with 2‐(2‐(benzofuran‐2‐ylsulfonylcarbamoyl)‐5‐methoxy‐1H‐indol‐1‐yl)acetic acid). Abstract : A series of triazolyl‐dihydroquinoline derivatives were synthesized and evaluated for their in vitro anti‐tubercular activity. The compounds 6a, 6g and 6j showed promising activity with MIC 3.13µg/mL. The structure and activity relationship was further supported by in silico molecular docking studies against the active site of pantothenate synthetase (PDB ID:3IVX).